Addition of liraglutide to overweight patients with type 2 diabetes treated with multiple daily insulin injections (MDI) with inadequate glycaemic control

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Mar 2022 Results of post hoc analysis comparing the effect of liraglutide to placebo on markers of insulin secretion in persons with type 2 diabetes treated with multiple daily insulin injections, published in the Journal of Diabetes and its Complications
15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
13 Jun 2017 Results assessing factors associated with HbA1c and weight changes, presented at the 77th Annual Scientific Sessions of the American Diabetes Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com